Vladimir R. Muzykantov mainly investigates Endothelium, Drug delivery, Pharmacology, Nanocarriers and Biochemistry. His Endothelium research includes elements of Oxidative stress, Inflammation, Endocytosis and ICAM-1, Cell adhesion molecule. His studies deal with areas such as Ex vivo, Neoplasms diagnosis and Rational design as well as Drug delivery.
His Pharmacology research is multidisciplinary, incorporating elements of Plasminogen activator, Lung, Immunology and Pathology. His study in Nanocarriers is interdisciplinary in nature, drawing from both Intercellular Adhesion Molecule-1, Biophysics and Liposome. In his research on the topic of Biochemistry, NADPH oxidase and Streptavidin is strongly related with Molecular biology.
Pharmacology, Endothelium, Biochemistry, Drug delivery and Molecular biology are his primary areas of study. His Pharmacology research includes themes of Plasminogen activator and Immunology, Fibrin. The concepts of his Endothelium study are interwoven with issues in Endothelial stem cell, Oxidative stress, Inflammation and Cell adhesion molecule, Cell biology.
When carried out as part of a general Biochemistry research project, his work on Biotinylation, Biotin, Enzyme and Superoxide dismutase is frequently linked to work in Conjugate, therefore connecting diverse disciplines of study. His Drug delivery study combines topics from a wide range of disciplines, such as Liposome and Drug. He has researched Molecular biology in several fields, including In vitro, Epitope, Antibody, Monoclonal antibody and Thrombin.
His primary scientific interests are in Drug delivery, Nanocarriers, Pharmacology, Inflammation and Targeted drug delivery. His research on Drug delivery focuses in particular on Drug carrier. His Nanocarriers research is multidisciplinary, incorporating perspectives in Biophysics, Ferritin, Cell adhesion molecule, Cell biology and Nanomedicine.
His work deals with themes such as Immunology, Sepsis, Thrombin and Biodistribution, which intersect with Pharmacology. His Inflammation research incorporates themes from Oxidative stress, Superoxide dismutase, Pathology, Endothelium and Lung injury. His Targeted drug delivery research integrates issues from Adhesion, ICAM-1, Primary Graft Dysfunction, Biochemistry and Nanogel.
His primary areas of investigation include Drug delivery, Nanocarriers, Pharmacology, Drug carrier and Inflammation. His Drug delivery study focuses on Targeted drug delivery in particular. His work in Pharmacology tackles topics such as Cell adhesion molecule which are related to areas like Endothelial stem cell, Intracellular and Apolipoprotein E.
Vladimir R. Muzykantov has included themes like Oxidative stress, Superoxide dismutase, Reactive oxygen species, Endothelium and Lung injury in his Inflammation study. His Oxidative stress study combines topics in areas such as Disease progression, Biophysics, Oxidation reduction and Immunology. His Endothelium study incorporates themes from Adipose tissue, Pathology and Circulatory system, Cardiology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Zhiliang Cheng;Ajlan Al Zaki;James Z. Hui;Vladimir R. Muzykantov.
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers.
Silvia Muro;Carmen Garnacho;Julie A Champion;John Leferovich.
Molecular Therapy (2008)
Endothelial NADPH Oxidase as the Source of Oxidants in Lungs Exposed to Ischemia or High K
Abu B. Al-Mehdi;Guochang Zhao;Chandra Dodia;Kasumi Tozawa.
Circulation Research (1998)
Drug delivery by red blood cells: vascular carriers designed by mother nature
Vladimir R. Muzykantov.
Expert Opinion on Drug Delivery (2010)
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1
Silvia Muro;Rainer Wiewrodt;Anu Thomas;Lauren Koniaris.
Journal of Cell Science (2003)
Targeting vascular (endothelial) dysfunction
Andreas Daiber;Sebastian Steven;Alina Weber;Vladimir V. Shuvaev.
British Journal of Pharmacology (2017)
1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage.
Yefim Manevich;Tom Sweitzer;Jhang Ho Pak;Sheldon I. Feinstein.
Proceedings of the National Academy of Sciences of the United States of America (2002)
Targeting of superoxide dismutase and catalase to vascular endothelium.
Vladimir R Muzykantov.
Journal of Controlled Release (2001)
European contribution to the study of ROS : a summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)
Javier Egea;Isabel Fabregat;Yves M Frapart;Pietro Ghezzi.
Redox biology (2017)
Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species.
Caryn Vadseth;Jose M. Souza;Leonor Thomson;Amy Seagraves.
Journal of Biological Chemistry (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: